A case of myocarditis following ChAdOx1 nCov-19 vaccination

Acta Cardiol. 2022 Nov;77(9):852-854. doi: 10.1080/00015385.2022.2040825. Epub 2022 Feb 21.

Abstract

Introduction: Myocarditis is an inflammatory disease of the myocardium, that might lead to reduced cardiac function and in the most severe cases to mortality. Although uncommon, it is a known adverse event after vaccination with coronavirus disease 2019 (COVID-19) mRNA vaccines. Here, we report the case of myocarditis following vaccination with a viral vector vaccine, ChAdOX1 nCoV-19.Case presentation: A 50-year-old male presented at the emergency department with shortness of breath, general malaise and fever, 5 days after receiving a second dose of the ChAdOx1 vaccine. Biochemical analysis revealed elevated serum CRP and troponin levels. Two weeks after initial presentation, a cardiac MRI showed belated contrast capitation in the left ventricle, confirming the diagnosis of myocarditis.Conclusions: To our knowledge, this is the first report of myocarditis following ChAdOx1 vaccination. Except for some case of myocarditis upon the Ad26COVS1 vaccine, no other cases were reported upon vaccination with the ChAdOX1 viral vector vaccines. With this report we would like to raise awareness about myocarditis as an adverse event following ChAdOx1 vaccination.

Keywords: AstraZeneca; COVID-19; ChAdOx1 nCov-19; myocarditis; vaccination.

Publication types

  • Case Reports

MeSH terms

  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Myocarditis* / chemically induced
  • Myocarditis* / diagnosis
  • Vaccination / adverse effects

Substances

  • ChAdOx1 nCoV-19